Abciximab use has been well associated with the development of thrombocytopenia at rates
between 2.5% and 5.6%, 1–4 and with the potentially life-threatening occurrence of acute
profound thrombocytopenia5, 6 at rates between 0.3% and 0.8%. 1, 2, 5, 6 Consequently,
the monitoring of platelet counts with abciximab use has become routine. In contrast,
eptifibatide has not been strongly associated with thrombocytopenia7 or acute profound
thrombocytopenia, 8–10 and the role of routine platelet monitoring with its use remains …